prostate carcinoma
Conditions
Interventions
The treatment group is given androgen blockage using Eligard 22.5 mg once and
Bicalutamide 50 mg daily for the duration of three months preceding BT. The
control group will receive BT immediately.
Sponsors
TweeSteden ziekenhuis
Eligibility
Age
18 Years to 99 Years
Inclusion criteria
Inclusion criteria: These are the inclusioncriteria: Patients with low and intermediate risk prostate cancer (according to Dutch guidelines) prostate volume between 35 and 55 cc a life expectancy of at least 10 years written informed consent
Exclusion criteria
Exclusion criteria: These are the exclusion criteria: Contra-indication for BT use of hormone suppressive therapy in the past or surgical castration. use of 5 alfa reductase in the last 6 months use of estrogens cognitive impairments negative decision for study participation by the hospitals* urology-radiotherapy meeting kidney or liver dysfunction history of myocardial infarction with present symptoms or CAD-induced heart failure
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Levels of PSA and testosterone over the 3-year follow-up period; | — |
Secondary
| Measure | Time frame |
|---|---|
| change in prostate volume+ other important variables: age, urinary complaints, complications, events. | — |
Countries
Netherlands
Outcome results
None listed